Advances in NASH/NAFLD at the 2022 SCSG Liver Symposium

December 18, 2022

Welcome!

Thank you for joining us for the Chronic Liver Disease Foundation's Advances in NASH/NAFLD symposium. 

Please select “Register/Take Course” to complete the following:

  • Pre-Test
  • Post-Test
  • Program Evaluation

Upon completion, you will receive your accreditation certificate. 

The pre-test will close on Sunday, December 18, at 7:15 AM PT.
The post-program activities will become available on Sunday, December 18, at 8:00 AM PT.

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists, hepatologists, nurse practitioners (NPs), physician assistants (PAs), and other healthcare professionals who are currently managing and treating patients with nonalcoholic steatohepatitis (NASH).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the benefits and limitations of current diagnostic modalities and treatment options for NAFLD/NASH
  • Describe recent evidence regarding new and emerging noninvasive diagnostic modalities for NASH
  • Describe the mechanisms of action of novel agents for the treatment of NASH
  • Discuss recent evidence regarding the safety and efficacy of emerging agents for the treatment of NASH in diverse patient populations
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 AMA PRA Category 1 Credit™ (Non- MD)
Course opens: 
12/07/2022
Course expires: 
12/18/2023
Event starts: 
12/18/2022 - 10:00am EST
Event ends: 
12/18/2022 - 11:00am EST
Rating: 
0

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and the Chronic Liver Disease Foundation (CLDF). The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

All faculty and staff involved in the planning or presentation of continuing education activities provided by the University of Cincinnati are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

All additional planning committee members, the University of Cincinnati staff and the Chronic Liver Disease Foundation (CLDF) staff have no relationships to disclose.

Learner Assurance Statement

The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members' significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Disclaimer Statement

The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees' professional development.

Americans with Disabilities Act

The event staff will be glad to assist you with any special needs (i.e., physical, dietary). For more information visit www.ChronicLiverDisease.org, email info@ChronicLiverDisease.org, or call 1-888-565-5321.

Provided by Accredited by
Supported by an educational grant from Novo Nordisk Inc.

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 AMA PRA Category 1 Credit™ (Non- MD)
Please login or register to take this course.